Open AccessP1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL‐WORLD UK STUDY
Author(s) -
Tivey A.,
Shotton R.,
Eyre T. A.,
Lewis D.,
Crosbie N.,
Nga E.,
Guerrero Camacho R.,
Swe W.,
Marr H.,
Rees C.,
Moule S.,
Sutton T.,
Wrench D.,
Thomas N.,
Wilson M.,
Bailey J.,
Prahladan M.,
Hodson A.,
Koppana M.,
Smith S.,
Jones S.,
Miall F.,
Norman J.,
Davies E.,
Hildyard C.,
Lowry L.,
Paneesha S.,
Qureshi I.,
Beech A.,
Bedford C.,
Everden A.,
Tucker D.,
Wright J.,
Goddard J.,
Nicholson T.,
Wilson J.,
Lord A.,
Jackson B.,
Flont M.,
Gibb A.,
Linton K.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847432.95668.eb
Subject(s) - medicine , ibrutinib , mantle cell lymphoma , rituximab , neutropenia , interim analysis , phases of clinical research , oncology , clinical trial , surgery , toxicity , lymphoma , leukemia , chronic lymphocytic leukemia